(Date:5/16/2008)...rstCall/ -- Tempo Participacoes,S.A. (Bovespa: TEM...ding,provider of healthcare administration service... services, announces today its results for the fir...formation contained herein,except where otherwise...,accordance with Brazilian Stock Exchange Commissi...
(Date:5/15/2008)...sing in Targeting Cancer Cells, ...ay 15 /PRNewswire-FirstCall/ -- Abbott scientists,...everal investigative,compounds in the company,s on... Clinical Oncology (ASCO) Annual Meeting, schedule... ABT-263, a Bcl-2 family protein,antagonist, and A...
(Date:5/15/2008)...ng cancer treatment for each individual, researche...resented a study suggesting a simple blood test ca...cacy for patients with metastatic breast cancer. ,...to determine if a particular cancer treatment is w...y significant radiographic changes in tumor size o...
(Date:5/15/2008)...tCall/ -- Digital Power,Corporation (Amex: DPW ) ...cial results for the first quarter ended March 31,...000 for the quarter ended,March 31, 2008, an incre...last year. An operating loss of $165,000 for the f...operating profit of $25,000 for the same quarter,l...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3(Date:5/15/2008)...Antiplatelet Therapy that, Combined, with Aspirin,...ix/Iscover and Aspirin, According to a New Rep...15 /- Decision Resources, one of the,...armaceutical and,healthcare issues, finds that Dai... in patient compared to Sanofi-Aventis/Bristol Mye...
(Date:5/15/2008)...ares Genous, Boston Scientific,s ...on Real-World Use of Genous, Stent,s Performance ... Dual-Antiplatelet ... OrbusNeich today announced,that multiple clinical...,support the use of the company,s Genous Bio-engin...
(Date:5/14/2008)...ire-FirstCall/ -- Progen,Pharmaceuticals Limited (...mpany has resumed patient enrolment in the phase 1...lyamine analogue, PG-11047 (formerly CGC-11047),fo...enced development of PG-11047 - the lead clinical,...owing its acquisition of,Cellgate, Inc earlier thi...
(Date:5/14/2008)... for cervical cancer prevention, GRAZ, Austria, M...xtended follow-up study show that GlaxoSmithKline ...ERVARIX(R) generates sustained high levels of,neut...rvical cancer-causing,human papillomavirus types f...f sustained neutralizing antibody levels observed ...
Breaking Medicine Technology:Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 14008 1EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 14008 2Colon Cancer Screening Laws Now Cover Half of U S Population 3861 1Colon Cancer Screening Laws Now Cover Half of U S Population 3861 2Colon Cancer Screening Laws Now Cover Half of U S Population 3861 3Colon Cancer Screening Laws Now Cover Half of U S Population 3861 4Colon Cancer Screening Laws Now Cover Half of U S Population 3861 5DURECT to Participate in Cowen Annual Healthcare Conference 14005 1Outcomes Improve for Non Hodgkin Lymphoma Patients 14002 1Outcomes Improve for Non Hodgkin Lymphoma Patients 14002 2...LIS, France, May 11, 2007 /PRNewswire-FirstCall/ -...ate on the phase 2a,study for NCX 1000, which is c...harma Inc. A preliminary analysis of 11 patients,...nsion confirmed,the safety profile of NCX 1000 but...ort the continuation of this clinical trial. As a,...
...(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,...peutics for the,treatment of musculoskeletal, meta... results of a preclinical study with,ACE-031 that ...se,muscle mass and strength in normal mice and in ...its negative regulators of muscle,to increase musc...
Other Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
Medicine Products: